– Multiregional Study Across Taiwan, South Korea , and Singapore Supports Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Single-Tablet Regimen for the Treatment of People with HIV Initiating Therapy and Individuals with Prior Antiretroviral Therapy – – Subanalysis of a Phase 3 Randomized Controlled Trial Demonstrates B/F/TAF Single-Tablet Regimen Well Tolerated and Effective Treatment in Adults of Asian Descent Living with HIV, as well as Those with HIV/HBV Co-Infected who are ART-Naïve – HONG KONG , June 27, 2024 /PRNewswire/ -- Gilead Sciences, Inc. today unveiled findings from two comprehensive studies examining the effectiveness and tolerability of the B/F/TAF single-tablet regimen for the treatment of adults with HIV who are treatment-naïve and treatment-experienced, as well as ART-naïve, HIV/HBV co-infected adults of Asian descent. The data selected for presentation at the hybrid Asia-Pacific AIDS and Co-Infections Conference (APACC) 2024, taking place 27 June to 29 June in Hong Kong , marks the first time that these findings have been featured at a regional conference.
BICtegravir Single Tablet Regimen Asia (BICSTaR Asia), which is one of two Asian-specific real-world investigations, is a 24-month study that aims to showcase the effectiveness and tolerability of B/F/TAF in the real-world setting, evaluating outcomes for both treatment-naïve individuals and those previously treated with other HIV regimens. Additionally, BICSTaR Asi.
